NASDAQ:KLRA

Kailera Therapeutics Q1 2026 Earnings Results & Report

Kailera Therapeutics logo
$12.20 -0.37 (-2.94%)
As of 04:00 PM Eastern

Kailera Therapeutics reported Q1 2026 earnings on May 26, 2026. The company reported EPS of -$3,650.00.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Kailera Therapeutics EPS Results

Actual EPS
-$3,650.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Kailera Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kailera Therapeutics Q1 2026 Earnings FAQ

Kailera Therapeutics (NASDAQ:KLRA) reported earnings of -$3,650.00 per share for Q1 2026. The report was announced on Tuesday, May 26, 2026.

Kailera Therapeutics Earnings Headlines

Kailera Therapeutics to Present at ObesityWeek 2026
Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.tc pixel
See More Kailera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kailera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kailera Therapeutics and other key companies, straight to your email.

About Kailera Therapeutics

Kailera Therapeutics (NASDAQ:KLRA) is a clinical-stage biopharmaceutical company developing medicines for obesity and related metabolic diseases. Its research focuses on treatments that act on biological pathways involved in appetite, weight regulation and metabolism.

The company’s pipeline includes investigational injectable and oral therapies, including programs designed to target GLP-1 and GIP receptors. These products are in development and are not approved for commercial use.

Founded in 2024, Kailera has secured development and commercialization rights outside Greater China to drug candidates discovered by Jiangsu Hengrui Pharmaceuticals. The company is based in Watertown, Massachusetts, and is led by President and Chief Executive Officer Ron Renaud.

View Kailera Therapeutics Profile